Are Dividends Built To Last At AstraZeneca plc And BP plc?

How safe are AstraZeneca plc’s (LON: AZN) and BP plc’s (LON: BP) Dividends?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Some dividends have staying power. Companies delivering enduring dividends tend to back such often-rising payouts with robust business and financial achievement.

Fragile dividends, meanwhile, arise because of weaker operational and financial characteristics. Those are the dividends to avoid. However, fragile dividends often tempt us because of high dividend yields.

How to tell the difference

Under the spotlight today, two FTSE 100 firms: AstraZeneca (LSE: AZN) the pharmaceutical supplier and BP (LSE: BP) the oil giant.

Should you invest £1,000 in Standard Chartered right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Standard Chartered made the list?

See the 6 stocks

These firms operate in different sectors, but they both have a reasonable dividend yield. At the recent share price of 4320p, AstraZeneca’s forward yield for 2016 is 4.3%. At 332p, BP’s is 7.8%.

Let’s run some tests to gauge business and financial quality, and score performance in each test out of a maximum five.

  1. Dividend record

Both firms maintained dividend payments over the past five-year trading period:

Ordinary dividends

2011

2012

2013

2014

2015

AstraZeneca (cents)

280

280

280

280

280 (e)

BP  (cents)

29

34

37

39.5

40 (e)

AstraZeneca’s dividend has been flat, but BP looks set to move its payment forward by 38% if 2015’s fourth quarter payment keeps up the established pattern. However, there is some doubt about whether the dividend is sustainable, due to the continuing low price of oil.

Both firms managed to maintain payments over the last few years. So, for their dividend records, I’m scoring AstraZeneca 2/5 and BP  4/5.

  1. Dividend cover

AstraZeneca expects its 2016 adjusted earnings to cover its dividend around 1.4 times. BP expects cover from earnings of just 0.9 times, which makes on-going dividend payments look vulnerable.

Both firms are running thin cover from adjusted earnings. I’m more comfortable with cover of around two times earnings. Of course, cash pays dividends, so it’s worth digging deeper into how well, or poorly, companies cover their dividend payouts with free cash flow.

On dividend cover from earnings, I’m scoring AstraZeneca  2/5 and BP 1/5.  

  1. Cash flow

Dividend cover from earnings means little if cash flow doesn’t support profits.

Here are the firms’ recent records on cash flow compared to profits:

AstraZeneca

2010

2011

2012

2013

2014

Operating profit ($m)

11,494

12,795

8,148

3,712

2,137

Net cash from operations ($m)

10,680

7,821

6,948

7,400

7,058

BP

 

 

 

 

 

Operating profit ($m)

(9,140)

33,001

14,157

27,803

2,197

Net cash from operations ($m)

13,616

22,154

20,479

21,100

32,754

Generally, both businesses see there cash flow support profits well. I’m scoring both firms 4/5 for cash flow.

  1. Level of gross debt

Interest payments on borrowed money compete with dividend payments for incoming cash flow. That’s why big debts are undesirable in dividend-led investments.

At the last count, BP’s borrowings were around 1.75 times the size of its net cash from operations, which seems manageable. AstraZeneca’s is even better at about 1.5 times its last-reported net cash from operations figure.

My attitude to debt in mature companies is quite harsh — I’m old-fashioned and believe they are better off without it — so, for their debt positions, BP gets 2/5 and AstraZeneca scores 3/5

  1. Degree of cyclicality

AstraZeneca’s share price moved from around 3,000p at the beginning of 2011 to 4,320p or so today, handing investors a 44% capital gain over the period to add to income from dividends.

BP slipped from around 500p at the start of 2011 to around 332p today, erasing investor dividend gains, and then some.

Those share-price movements act as a clue to the degree of cyclicality inherent in each sector. At one end of the cyclicality scale, we have BP, a business joined at the hip with macro-cycles and with little control over its own selling prices as the price of oil dances up and down to the tune of supply and demand.

At the other end of the cyclicality scale sits AstraZeneca, a firm well placed in a consumable market with high barriers to entry, and a structural trend locked on a course of rising demand. Patent expiry issues move in cycles, but they are cycles the firm may control by keeping up investment in research and development.

Of the two firms, in terms of cyclicality AstraZeneca best supports a long-term dividend-led investment strategy. I’m scoring BP 1/5 and AstraZeneca 4/5.

Putting it all together

Here are the final scores for these firms:

 

AstraZeneca

BP

Dividend record

2

4

Dividend cover

2

1

Cash flow

4

4

Level of gross debt

3

2

Degree of cyclicality

4

1

Total score out of 25

15

12

Neither firm is perfect but I’m inclined to put greater weight on some factors over others. For example, BP’s finances look reasonable after a period of relative prosperity, which boosts some of the scores. The current year’s results are not in yet, though, and the persistent low price of oil will surely affect the firm’s dividend outlook from here. Looking at BP’s share-price performance the effects of cyclicality are difficult to predict.

AstraZeneca’s operations, though, seem far more stable. The dynamics of the pharmaceutical sector gives AstraZeneca a fair chance of restoring its profitability from here, which could work well for a long-term, dividend-led investment in the firm over the coming years.

Of course, there are plenty of other passive income opportunities to explore. And these may be even more lucrative:

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

Here’s why Tesla stock just rocketed 22.7%! Is it time to buy?

This writer wonders whether the news that sent Tesla stock soaring yesterday is a true gamechanger for the electric vehicle…

Read more »

Investing Articles

2 quality UK stocks to consider buying as share prices rally

With UK stocks moving higher, it might look as though investors with cash on hand have missed their chance. But…

Read more »

Investing Articles

How much £10,000 invested in Lloyds shares is forecast to be worth in 12 months

Harvey Jones is looking past today's stock market volatility to see where Lloyds shares may stand in a year's time.…

Read more »

Investing Articles

How Warren Buffett stays ahead of the stock market

When share prices fall, everyone suddenly wants to be like Warren Buffett. But what’s the secret to the Berkshire Hathaway…

Read more »

Investing Articles

Cheap UK dividend shares to consider buying right now

We're only just past the first quarter of 2025, but it already looks like the year could be another good…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

What the heck is going on with the Barclays share price now?

The Barclays share price surged 25% as the market open on 10 April. Once again, the volatility’s been driven by…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

What the devil’s going on with the HSBC share price?

The HSBC share price has actually been less volatile than some of its peers, despite its Chinese operations suggesting it’s…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Are Tesco shares a screaming buy after sinking to 9-month lows?

Tesco shares continue to experience price weakness as signs of mounting competition grow. But is it now too cheap to…

Read more »